Format

Send to

Choose Destination
See comment in PubMed Commons below
Am Heart J. 2014 May;167(5):653-9.e4. doi: 10.1016/j.ahj.2014.02.010. Epub 2014 Mar 1.

Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.

Collaborators (348)

Kerby JD, Wang HE, Bosarge PL Jr, Pittet J, Stephens SW, Williams CR, Gray R, Gray P, Cobb G, Lowe R, Richardson D, Boyd S, Hallmark R, Wade D, West E, Underwood D, Hambright D, Gilford W, Christenson J, Connolly H, Pennington S, Hall C, Todorova D, Aguirre C, Schlamp R, Wand R, Straight R, Goulding J, Balfour N, Ganstal A, Idris AH, Fowler R, Miller R, Pepe P, Arellano-Cruz P, Bryant B, Castillo M, Climer D, Cooper T, Dickens A, Dudek S, Dykes K, Gallegos D, Moffat M, Owens P, Podias C, Ray D, Saniei S, Sledge B, Waks D, Zunner A, Beeson J, Benitez F, Corder S, Dees L, Deutsch S, Gamber M, Gamez G, Hamessley T, Heath S, Isaacs M, Kayea T, LaChance R, Lovato S, Martin L, McKee LA, Muse B, Navarro K, Price S, Rosenberger P, Seals N, Sides J, Swavey T, Tomasovic G, Wade M, Black S, Broders C, Bush M, Garrett J, Hum L, Oberg T, Ramsay M, Simonson R, Woodward P, Aufderheide TP, Pirrallo RG, Brasel KJ, Colella M, Klein JP, Brandt J, Bialkowski W, Boettcher M, Jasti J, Gauger S, Sandoval C, Hermanson B, Burpee K, Price G, Hessenthaler A, Mena M, Zellner S, Quering B, Jasti J, Goldberg M, Herdeman C, Zeisse M, Qaisar T, Von W, Wuerl A, Mccormick K, Walsh P, Forster R, Pukansky L, Sternig K, Viel E, Chin E, Krueger K, Szewczuga D, Funk R, Jacobsen G, Spitzer J, Cohn J, Jankowski M, Whitaker R, Rohlfing M, Rosandish T, Remington A, Knitter J, Ugaste R, Saidler T, Reminga T, Shepherd D, Holzhauer P, Rubin J, Skold C, Alvarez O, Harkins H, Barthell E, Haselow W, Yee A, Whitcomb J, Castro EE, Motarjeme S, Coogan P, Rader K, Glaspy J, Gerschke G, Croft H, Brin M, Wilson C, Johnson A, Kumprey W, Ateyyah KA, Gourlay D, Kaslow O, Stiell I, Vaillancourt C, Wells GA, Yelle JD, Clement C, Lepage G, Banek J, Gerrard P, Whitham V, Marcantonio A, Gleeson A, Munkley D, Affleck A, Bradford P, Smith K, Ferron R, Lutz-Graul K, Pedulla J, Gale N, Gates W, Monas J, Mellow R, Hedges C, Poole L, Graham E, Daya MR, Schmidt TA, Griffiths DE, Zive DM, Kampp M, Vandenheuvel K, Sidhu A, Le N, Stouffer J, Wittwer L, Muhr MD, Griffith J, Free C, Warden CR, Gorman K, Beeler T, Conway W, Newton C, Geiger C, Colvin J, Hollingsworth M, O'Brien D, Shertz M, Malone S, Keim E, Sahni R, DeHart S, Freedman S, Moreno R, Chin J, Snyder S, Boyce D, Welk A, Funk A, Murphy W, Charleston M, Stevens M, Schult E, Sullivan S, Getsfrid J, Hoskins G, Shields C, Bishop TJ, Albrich M, Carnevale T, Best B, Kummer K, Arnold K, Davis D, Vilke G, Aker DK, Garcia E, Haynes B, Dunford J, Norton V, Mebust D, Kramer M, Morikado L, Grad M, Linnik W, Carter S, Hare M, Kudenchuk PJ, Kudenchuk P, Rea T, Ragsdale S, Solberg D, Sampson D, Olsufka M, Perry S, Larsen J, Morrison LJ, Dorian P, Verbeek P, Cheskes S, Moran P, Byers A, Heckaden B, McLeod B, Emerson B, Harrison C, Falconer D, Braga D, Burgess G, Mueller H, Walker J, Bath K, Wernham L, Lewarne L, Chen L, Reymen M, Zielinski M, Common M, Kadic M, Gaudio M, Qovaizi M, Liu N, Gavrylyuk O, Oke P, D'Souza P, Lui S, Brown S, Mathew S, Perreira T, Benson A, Bodo A, Mokedanz D, Wright G, Mcauley G, Sage G, Rosswell L, Addley M, Norwicky R, Gorsline S, Driscoll S, McConnell S, Jones V, Beckett W, Baker A, Slutsky A, Lefeuvre C, Simone C, Scales D, McRitchie D, Letovsky EE, Clasky H, Hutchinson J, Bowen J, Meyer J, Chien J, Christian M, Welsford M, Ferguson N, Brooks S, Weisfeldt M, Ornato JP, Sopko G, Egan D, Lathrop D, Nickens PD, Wu C, Mitchell P, Shah M, Rosenberg E, Pearson G, May S, Nichol G, Powell J, Schmicker R, Leroux B, Brown S, Emerson S, Gest A, van Belle G, Carson J, Kirdpoo W, Bergsten-Buret B, Moore R, Berhorst J, Prince D, Torres C, Case E, Guffey D, Sanchez B, Zelnick L, Devlin SM, Van Ottingham L, Sears G.

Author information

1
Department of Medicine, Division of Cardiology, University of Washington, Seattle, WA; Public Health-Seattle & King County, Seattle, WA. Electronic address: kudenchuk@u.washington.edu.
2
Department of Biostatistics, Clinical Trial Center, University of Washington, Seattle, WA.
3
Department of Emergency Medicine, Oregon Health & Science University, Portland, OR.
4
RESCU, Keenan Research Centre, St Michael's Hospital, Division of Emergency Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
5
Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
6
Public Health-Seattle & King County, Seattle, WA; Department of Medicine, University of Washington, Seattle, WA.
7
Medical College of Wisconsin, Milwaukee, WI.
8
Department of Emergency Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada.
9
Seattle Fire Department, Seattle, WA.
10
Peace Health Southwest Medical Center, Vancouver, WA.
11
Department of Emergency Medicine, Medical College of Wisconsin, Milwaukee WI.
12
Department of Emergency Medicine, University of Alabama, Birmingham, AL.
13
Plano Fire Rescue, Plano, TX.
14
National Heart Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD.
15
Department of Medicine, Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Abstract

BACKGROUND:

Despite their wide use, whether antiarrhythmic drugs improve survival after out-of-hospital cardiac arrest (OHCA) is not known. The ROC-ALPS is evaluating the effectiveness of these drugs for OHCA due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia (VF/VT).

METHODS:

ALPS will randomize 3,000 adults across North America with nontraumatic OHCA, persistent or recurring VF/VT after ≥1 shock, and established vascular access to receive up to 450 mg amiodarone, 180 mg lidocaine, or placebo in the field using a double-blind protocol, along with standard resuscitation measures. The designated target population is all eligible randomized recipients of any dose of ALPS drug whose initial OHCA rhythm was VF/VT. A safety analysis includes all randomized patients regardless of their eligibility, initial arrhythmia, or actual receipt of ALPS drug. The primary outcome of ALPS is survival to hospital discharge; a secondary outcome is functional survival at discharge assessed as a modified Rankin Scale score ≤3.

RESULTS:

The principal aim of ALPS is to determine if survival is improved by amiodarone compared with placebo; secondary aim is to determine if survival is improved by lidocaine vs placebo and/or by amiodarone vs lidocaine. Prioritizing comparisons in this manner acknowledges where differences in outcome are most expected based on existing knowledge. Each aim also represents a clinically relevant comparison between treatments that is worth investigating.

CONCLUSIONS:

Results from ALPS will provide important information about the choice and value of antiarrhythmic therapies for VF/VT arrest with direct implications for resuscitation guidelines and clinical practice.

PMID:
24766974
PMCID:
PMC4014351
DOI:
10.1016/j.ahj.2014.02.010
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center